CD40 and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC), CD40 agonist therapy—particularly when combined with chemotherapy—has demonstrated disease stabilization and improved immune cell infiltration, as observed in early-phase trials using APX005M and selicrelumab (189).